Skip to main content
. 2023 Jan 24;13:1092704. doi: 10.3389/fimmu.2022.1092704

Figure 2.

Figure 2

Dynamic alterations in the phenotype of circulating EMVs following FCM application. (A) Analysis of the phenotype of circulating EMVs with assessment of the constitutive endothelial markers CD31 (PECAM-1) and CD144 (VE-Cadherin) and the inducible markers CD62E (E-selectin) and CD54 (ICAM-1). *p < 0.05 vs. HF patients at baseline for the respective EMV phenotype. (B) Evaluation of the EMV CD62E+/CD31+ and CD54+/CD144+ ratio to determine the balance of activation vs. apoptosis related generation of EMVs. *p < 0.05 vs. the respective ratio in healthy controls, #p < 0.05 vs. the respective ratio in HF patients at baseline. (C) Kinetics of various EMV phenotypes following FCM injection in HF patients. Data points for each phenotype marker are connected by a broken line for the sole reason to enhance readability (D, E) Kinetics of the EMV CD62E+/CD31+ and CD54+/CD144+ ratio at baseline and following FCM injection in HF patients. *p < 0.05 vs. baseline for the respective EMV ratio.